Weight Loss

Healio and Endocrine Today editors have compiled the top news about obesity from 2021.

Novo Nordisk announced it cannot meet demand in the U.S. for its recently approved weight-loss drug semaglutide for at least the first half of 2022.

Second-generation obesity medications such as semaglutide can improve cardiometabolic health and induce weight loss of at least 10%, according to W. Timothy Garvey, MD, FACE, MABOM.

Semaglutide and other obesity medications that can induce weight loss of at least 10% can change the way providers approach the treatment of obesity, according to a speaker.

Intensive lifestyle therapy in children and adolescents with nonalcoholic fatty liver disease led to significant weight loss and improvements in liver steatosis and fibrosis, according to study results.

More than half of young adults participating in a weight-loss intervention had a weight gain above baseline at 3 years, according to study data published in Obesity.

Multiple dietary pathways can lead to weight loss, and adherence to a weight-loss program is a better predictor for success than the type of eating pattern a person chooses, according to a speaker.

The stewards of the Mayo Clinic Diet recently updated the 72-year-old eating plan.

Presence of obstructive sleep apnea or CPAP use did not impact weight or glycemic outcomes at 2 months among adults with class 3 obesity, according to new research published in BMC Endocrine Disorders.

Among patients with fibrotic interstitial lung disease, low BMI and weight loss were independently associated with increased 1-year mortality, researchers reported in Chest.